Ignite Creation Date:
2025-12-25 @ 2:23 AM
Ignite Modification Date:
2025-12-26 @ 5:28 PM
Study NCT ID:
NCT04880434
Status:
COMPLETED
Last Update Posted:
2025-11-17
First Post:
2021-04-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
Sponsor:
Kite, A Gilead Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-04-27
Start Date Type:
ACTUAL
Primary Completion Date:
2025-06-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-06-17
Completion Date Type:
ACTUAL
First Submit Date:
2021-04-30
First Submit QC Date:
None
Study First Post Date:
2021-05-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-14
Last Update Post Date:
2025-11-17
Last Update Post Date Type:
ESTIMATED